DR. GARY WÖRTZ
Gary Wörtz, MD is a board certified ophthalmologist from Lexington, KY with a passion for improving the field of eye care through innovation, research and education. His journey began at Asbury University where he graduated magna cum laude with a degree in Chemistry. He completed his medical doctorate at the University of Louisville, where he graduated with honors and his ophthalmology residency at the University of Kentucky where he served as Chief Resident. As Chief Resident, he was recognized by the American Colleges of Eye Surgeons for superior surgical skills in cataract surgery and was selected as the national winner of the prestigious Bloomberg Memorial Resident Competition in 2008.
Since finishing his residency, Dr. Wörtz has found many opportunities to stay engaged in cutting edge research and advanced surgical ophthalmology. He has been a Principal Investigator in numerous FDA pharmaceutical trials, most notably Lifitigrast (Xiidra), which has recently become the second prescription medication approved for the treatment of dry eye. In the field of medical device innovation, Dr. Wörtz has numerous patents, both in the US and Internationally, for the technology he is bringing to market through his startup, Omega Ophthalmics.
Clinically, Dr. Wörtz is one of the busiest cataract and refractive surgeons in US drawing patients from all throughout the region. His wealth of experience and expertise has been recognized by the British trade journal, The Ophthalmologist, who named him to their global “Top 40 ophthalmologist under 40 Power List”. Ocular Surgery News has also named him to their Premier Surgeon 300 list of top innovators in refractive cataract surgery. Dr. Wörtz is on the editorial board of numerous publications including Cataract and Refractive Surgery Today, Advanced Ocular Care, OSN, and Millennial Eye. He consults widely to the ophthalmic industry and is a frequent speaker at educational symposiums and ophthalmic meetings.
From clinical research to daily patient interaction, Dr. Wörtz understands the physiology of ocular surface disease and the importance of managing these conditions especially if you are considering eye surgery.